Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 06-Feb-24 10:27 AM View:  | Evans Carl Anthony Director | Cns Pharmaceuticals, Inc. (CNSP) | 01-Feb-24 | Private Purchase | 33,333 | $0.30 | $9,999.90 | 26666% 0.13K to 33.46K | |
| 06-Feb-24 10:27 AM View: | Climaco John M Chief Executive Officer Director | Cns Pharmaceuticals, Inc. (CNSP) | 01-Feb-24 | Private Purchase | 166,666 | $0.30 | $49,999.80 | 340% 49.01K to 215.68K | |
| 06-Feb-24 10:28 AM View: | Gumulka Jerzy Director | Cns Pharmaceuticals, Inc. (CNSP) | 01-Feb-24 | Private Purchase | 33,333 | $0.30 | $9,999.90 | 345% 9.67K to 43.01K | |
| 06-Feb-24 10:27 AM View: | Downs Christopher Chief Financial Officer | Cns Pharmaceuticals, Inc. (CNSP) | 01-Feb-24 | Private Purchase | 66,666 | $0.30 | $19,999.80 | 181% 36.77K to 103.44K | |
| 23-Aug-23 8:00 AM View: | Downs Christopher Chief Financial Officer | Cns Pharmaceuticals, Inc. (CNSP) | 22-Aug-23 | Purchase | 27,000 | $1.27 | $34,176.60 | 276% 9.77K to 36.77K | |
| 16-Aug-23 4:01 PM View: | Climaco John M Chief Executive Officer Director | Cns Pharmaceuticals, Inc. (CNSP) | 16-Aug-23 | Purchase | 2,750 | $1.80 | $4,944.50 | 6% 46.26K to 49.01K | |
| 01-May-23 10:00 PM View: | Downs Christopher Chief Financial Officer | Cns Pharmaceuticals, Inc. (CNSP) | 28-Apr-23 | Option Exercise | 521 | -- | -- | 6% 9.25K to 9.77K | |
| 01-May-23 10:00 PM View: | Climaco John M Chief Executive Officer Director | Cns Pharmaceuticals, Inc. (CNSP) | 28-Apr-23 | Option Exercise | 1,250 | -- | -- | 3% 45.01K to 46.26K | |
| 21-Apr-23 7:58 AM View: | Gumulka Jerzy Director | Cns Pharmaceuticals, Inc. (CNSP) | 19-Apr-23 | Purchase | 2,500 | $1.70 | $4,250.00 | 35% 7.17K to 9.67K | |
| 18-Apr-23 8:00 AM View: | Downs Christopher Chief Financial Officer | Cns Pharmaceuticals, Inc. (CNSP) | 17-Apr-23 | Purchase | 3,100 | $3.20 | $9,920.00 | 50% 6.15K to 9.25K | |
| 14-Apr-23 4:20 PM View: | Climaco John M Chief Executive Officer Director | Cns Pharmaceuticals, Inc. (CNSP) | 12-Apr-23 | Market Purchase | 15,000 | $0.69 | $10,408.50 | 50% 30.01K to 45.01K | 4% |
| 17-Apr-23 8:17 AM View: | Gumulka Jerzy Director | Cns Pharmaceuticals, Inc. (CNSP) | 10-Apr-23 | Market Purchase | 7,173 | $0.74 | $5,308.02 | 100% 0 to 7.17K | (3%) |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 28-Mar-23 | Sale | 10,000 | $1.04 | $10,400.00 | (6%) 166.81K to 156.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 27-Mar-23 | Sale | 5,000 | $1.09 | $5,450.00 | (3%) 171.81K to 166.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 24-Mar-23 | Sale | 5,000 | $1.08 | $5,400.00 | (3%) 176.81K to 171.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 23-Mar-23 | Sale | 10,000 | $1.08 | $10,800.00 | (5%) 186.81K to 176.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 22-Mar-23 | Sale | 5,000 | $1.08 | $5,400.00 | (3%) 191.81K to 186.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 21-Mar-23 | Sale | 5,000 | $1.10 | $5,500.00 | (3%) 196.81K to 191.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 20-Mar-23 | Sale | 5,000 | $1.08 | $5,400.00 | (2%) 201.81K to 196.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 17-Mar-23 | Sale | 5,000 | $1.13 | $5,650.00 | (2%) 206.81K to 201.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 16-Mar-23 | Sale | 5,000 | $1.24 | $6,200.00 | (2%) 211.81K to 206.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 15-Mar-23 | Sale | 5,000 | $1.22 | $6,100.00 | (2%) 216.81K to 211.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 14-Mar-23 | Sale | 5,000 | $1.35 | $6,750.00 | (2%) 221.81K to 216.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 13-Mar-23 | Sale | 5,000 | $1.30 | $6,500.00 | (2%) 226.81K to 221.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 10-Mar-23 | Sale | 5,000 | $1.29 | $6,450.00 | (2%) 231.81K to 226.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 09-Dec-22 | Sale | 2,798 | $2.43 | $6,799.14 | (1%) 234.6K to 231.81K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 08-Dec-22 | Sale | 5,500 | $2.40 | $13,200.00 | (2%) 240.1K to 234.6K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 07-Dec-22 | Sale | 5,500 | $2.46 | $13,530.00 | (2%) 245.6K to 240.1K | |
| 01-Aug-23 5:10 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 06-Dec-22 | Private Sale | 5,500 | $2.47 | $13,585.00 | (2%) 251.1K to 245.6K | |
| 14-Mar-22 9:40 AM View: | Downs Christopher Chief Financial Officer | Cns Pharmaceuticals, Inc. (CNSP) | 11-Mar-22 | Grant | 33,000 | $0.31 | $10,230.00 | 22% 151.5K to 184.5K | |
| 09-Mar-22 2:34 PM View: | Evans Carl Anthony Director | Cns Pharmaceuticals, Inc. (CNSP) | 08-Mar-22 | Grant | 3,750 | $0.27 | $1,005.00 | 100% 0 to 3.75K | |
| 08-Mar-22 8:30 AM View: | Climaco John M Chief Executive Officer Director | Cns Pharmaceuticals, Inc. (CNSP) | 07-Mar-22 | Grant | 35,000 | $0.28 | $9,835.00 | 4% 905.3K to 940.3K | |
| 09-Mar-22 2:34 PM View: | Keyes Jeffry R. Director | Cns Pharmaceuticals, Inc. (CNSP) | 07-Mar-22 | Grant | 11,100 | $0.30 | $3,294.48 | 100% 0 to 11.1K | |
| 07-Dec-21 8:30 AM View: | Downs Christopher Chief Financial Officer | Cns Pharmaceuticals, Inc. (CNSP) | 06-Dec-21 | Market Purchase | 5,000 | $0.94 | $4,701.50 | 3% 146.5K to 151.5K | (< 1%) |
| 22-Nov-21 8:47 AM View: | Downs Christopher Chief Financial Officer | Cns Pharmaceuticals, Inc. (CNSP) | 19-Nov-21 | Market Purchase | 4,500 | $1.15 | $5,191.65 | 3% 142.0K to 146.5K | (1%) |
| 18-Nov-21 8:07 PM View: | Climaco John M Chief Executive Officer Director | Cns Pharmaceuticals, Inc. (CNSP) | 16-Nov-21 | Grant | 5,000 | $1.28 | $6,400.00 | < 1% 900.3K to 905.3K | (12%) |
| 25-Aug-20 7:11 PM View: | Downs Christopher Chief Financial Officer | Cns Pharmaceuticals, Inc. (CNSP) | 24-Aug-20 | Purchase | 142,000 | $2.04 | $289,680.00 | 100% 0 to 142.0K | |
| 25-Jan-22 4:05 PM View: | Priebe Waldemar 10% Owner | Cns Pharmaceuticals, Inc. (CNSP) | 05-May-20 | Disposition (other) | 1,495,870 | -- | -- | (17%) 9.03M to 7.53M |
